A landmark UK trial aiming to revolutionise prostate cancer screening has begun testing its first male participants. The ...

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

The collaboration includes the initial validation and deployment of Ibex Prostate within HNL Lab Medicine’s LDT workflow.

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...

A new at-home saliva test for prostate cancer could outperform current testing methods, a new study suggests. Researchers have developed a simple spit test, that can be performed at home and does not ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

CAMBRIDGE, England--(BUSINESS WIRE)--Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate ...

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer is ...

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending drug abiraterone, in clinical trial results presented by scientists from ...

Former President Joe Biden received his last known blood test to check for prostate cancer in 2014, a spokesperson said Tuesday — two days after Biden revealed he has an aggressive form of prostate ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and ...